中国动脉硬化杂志2009，Vol.17Issue(7)：551-554,4.
恩度联合紫杉醇和顺铂治疗晚期非小细胞肺癌的疗效及心血管毒性
The Therapeutic Effect and Cadiovascular Adverse Reaction of Endostar Combined with Paclitaxel and Cisplatin on Advanced Non-Small-Cell Lung Cancer
文美玲 1李宝秀 2梁庆模1
作者信息
- 1. 南华大学附属南华医院,湖南省衡阳市,421002
- 2. 广州市第一人民医院,广东省广州市,510180
- 折叠
摘要
Abstract
Aim To observe the therapeutic effect and cadiovaseular adverse reaction of rh-endostatin injection (YH-16 ,Endestar) combined with paclitaxel and cisplatin on advanced non-small-cell lung cancer( NSCLC ). Meth-ods Endostar combined with paclitaxel and cisplatin were administrated to 43 advanced non-small-cell lung cancer cases of stage Ⅲ-Ⅳ. Every course lasted 3 weeks, and all cases were evaluated after 2 courses at least;and safety was evalua-ted after one course. Results The objective response rate ( ORR ) was 48.79% ( 21/43 ) and disease control rate ( DCR) was 81.4 % ( 35/43 ), 1-year overall survival rate was 51.2%, median survival time was 12.2 months. The quality of life ( QOL ) were improved on 29 cases ( 67.44% ) , decreased on 6 cases ( 6/43 ). The occurrence rates of G3/4 toxicities were low, including neutropenia (11.63%, 5/43 ), thrombecytopenia (6.98%, 3/43 ), nausea/vomiting (4.65%, 2/43 ). These toxicities were mainly related with the chemotherapy agents. Conclusion Endostar com-bined paclitaxel and cisplatin as the first line on advanced non-small-cell lung cancer is highly effective and safe. The QOL of patients with advanced lung cancer may be improved by endostar combined with the paclitaxel and cisplatin chemo-therapy. It indicates that endostar has synergetic effects on some of eytotoxic agents or reverses tumor drug resistance such as paclitaxel and cisplatin. It is worthy of clinical generalization and further clinical observation.关键词
恩度/紫杉醇/顺铂/晚期非小细胞肺癌/抗肿瘤血管形成Key words
Endestar/Paelitaxcl/Cisplatin/Advanced Non-Small-Cell Lung Cancer/Antiangingenesis分类
医药卫生引用本文复制引用
文美玲,李宝秀,梁庆模..恩度联合紫杉醇和顺铂治疗晚期非小细胞肺癌的疗效及心血管毒性[J].中国动脉硬化杂志,2009,17(7):551-554,4.
